These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 14967167)

  • 1. Determination of plasma prothrombin levels by a novel Ca2+-dependent prothrombin activator (CA-1) in patients with chronic liver diseases.
    Nomura F; Shimizu S; Ohyama M; Sunaga M; Yokosuka O; Ebara M; Saisho H
    Clin Chim Acta; 2004 Mar; 341(1-2):123-6. PubMed ID: 14967167
    [No Abstract]   [Full Text] [Related]  

  • 2. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
    Nakamura S; Nouso K; Sakaguchi K; Ito YM; Ohashi Y; Kobayashi Y; Toshikuni N; Tanaka H; Miyake Y; Matsumoto E; Shiratori Y
    Am J Gastroenterol; 2006 Sep; 101(9):2038-43. PubMed ID: 16848811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged prothrombin time, Factor VII and activated FVII levels in chronic liver disease are partly dependent on Factor VII gene polymorphisms.
    Grimaudo S; Craxi A; Gentile S; Di Paolantonio T; Vaccaro A; Venezia G; Lo Coco L; Savella R; Usticano A; Capone F; Mariani G
    Dig Liver Dis; 2005 Jun; 37(6):446-50. PubMed ID: 15893284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
    Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
    Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A discussion of standardization for prothrombin time in patients with advanced liver diseases].
    Li Q; Cong YL; Wang BE; Jia JD; Chen Y; Zhang FK; Ou XJ; Wei YX; Ma H
    Zhonghua Gan Zang Bing Za Zhi; 2005 Feb; 13(2):128-31. PubMed ID: 15727702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A quantitative study of the relationship between levels of liver fibrosis markers in sera and fibrosis stages of liver tissues of patients with chronic hepatic diseases].
    Ding XJ; Li SB; Li SZ; Liu HS; Liu B; Xu FM; Gu RW
    Zhonghua Gan Zang Bing Za Zhi; 2005 Dec; 13(12):911-4. PubMed ID: 16381637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating vascular endothelial growth factor levels are decreased in patients with chronic hepatitis and liver cirrhosis depending on the degree of hepatic damage.
    Desideri G; Ferri C
    Clin Sci (Lond); 2000 Aug; 99(2):159-60. PubMed ID: 10918050
    [No Abstract]   [Full Text] [Related]  

  • 9. Chromogranin A levels in chronic liver disease and hepatocellular carcinoma.
    Massironi S; Fraquelli M; Paggi S; Sangiovanni A; Conte D; Sciola V; Ciafardini C; Colombo M; Peracchi M
    Dig Liver Dis; 2009 Jan; 41(1):31-5. PubMed ID: 18762462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Blood content of testosterone, progesterone and aldosterone in patients with chronic hepatitis and liver cirrhosis].
    Rosin IuA
    Vrach Delo; 1984 Sep; (9):36-8. PubMed ID: 6506637
    [No Abstract]   [Full Text] [Related]  

  • 11. Hemostasis and global fibrinolytic capacity in chronic liver disease.
    Aytac S; Turkay C; Bavbek N; Kosar A
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):623-6. PubMed ID: 17890949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concentration of prothrombin fragment 1 + 2 (f1 + 2) in patients with liver cirrhosis and chronic hepatitis C infection.
    Fota-Markowska H; Modrzewska R; Krzowska-Firych J; Lis-Tønder J; Borowicz I
    Ann Univ Mariae Curie Sklodowska Med; 2004; 59(2):4-7. PubMed ID: 16146040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Estrogen content of the blood of men with chronic hepatitis and liver cirrhosis in various phases of the disease].
    Zhukov SA; Khazanov AI; Gerasimov GM
    Voen Med Zh; 1984 Oct; (10):32-4. PubMed ID: 6506519
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical implications of measurement of serum nuclear matrix protein levels in patients with liver disease.
    Shimizu Y; Nakano I; Katano Y; Shimizu H; Fukuda Y
    Hepatogastroenterology; 2005; 52(66):1809-13. PubMed ID: 16334782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Enzyme activity and dynamics of blood levels of microelements during the complex treatment of chronic liver diseases].
    Neĭko VE
    Vrach Delo; 1985 Jun; (6):61-3. PubMed ID: 4024589
    [No Abstract]   [Full Text] [Related]  

  • 16. Prothrombin antigen and coagulant activity in patients with liver disease.
    Corrigan JJ; Jeter M; Earnest DL
    JAMA; 1982 Oct; 248(14):1736-9. PubMed ID: 7120594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of oxidant stress in Wilson's disease and non-Wilsonian chronic liver disease in childhood.
    Dalgiç B; Sönmez N; Biberoğlu G; Hasanoğlu A; Erbaş D
    Turk J Gastroenterol; 2005 Mar; 16(1):7-11. PubMed ID: 16252181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of serum fibrosis index in patients with chronic hepatitis and its relationship to histological activity index.
    Elmetwally IM; Elmahalaway AM; Abuhashem SH; Ahmed AM
    Saudi Med J; 2009 May; 30(5):638-46. PubMed ID: 19417962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prothrombin (factor II) in hepatic diseases].
    Mannucci PM; Lobina GF; Craveri A; Bragotti R; Cerrini R
    G Clin Med; 1968 Dec; 49(12):1311-25. PubMed ID: 5737500
    [No Abstract]   [Full Text] [Related]  

  • 20. Distribution of the heterogeneity of des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma.
    Uehara S; Gotoh K; Handa H; Tomita H; Senshuu M
    J Gastroenterol Hepatol; 2005 Oct; 20(10):1545-52. PubMed ID: 16174072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.